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Abstract
Cigarette smoking is associated with a decreased incidence of Parkinson disease (PD) through unknown mechanisms.
Interestingly, a decrease in the numbers of a4b2 nicotinic acetylcholine receptors (a4b2-nAChRs) in PD patients suggests an
a4b2-nAChR-mediated cholinergic deficit in PD. Although oligomeric forms of a-synuclein have been recognized to be toxic
and involved in the pathogenesis of PD, their direct effects on nAChR-mediated cholinergic signaling remains undefined.
Here, we report for the first time that oligomeric a-synuclein selectively inhibits human a4b2-nAChR-mediated currents in
a dose-dependent, non-competitive and use-independent manner. We show that pre-loading cells with guanyl-59-yl
thiophosphate fails to prevent this inhibition, suggesting that the a-synuclein-induced inhibition of a4b2-nAChR function is
not mediated by nAChR internalization. By using a pharmacological approach and cultures expressing transfected human
nAChRs, we have shown a clear effect of oligomeric a-synuclein on a4b2-nAChRs, but not on a4b4- or a7-nAChRs,
suggesting nAChR subunit selectivity of oligomeric a-synuclein-induced inhibition. In addition, by combining the size
exclusion chromatography and atomic force microscopy (AFM) analyses, we find that only large (.4 nm) oligomeric a-
synuclein aggregates (but not monomeric, small oligomeric or fibrillar a-synuclein aggregates) exhibit the inhibitory effect
on human a4b2-nAChRs. Collectively, we have provided direct evidence that a4b2-nAChR is a sensitive target to mediate
oligomeric a-synuclein-induced modulation of cholinergic signaling, and our data imply that therapeutic strategies targeted
toward a4b2-nAChRs may have potential for developing new treatments for PD.
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Introduction
Parkinson disease (PD) is one of the most common neurode-
generative disorders affecting more than half a million people in
the United States, with annual costs estimated at 10 billion dollars
[1]. The neuropathological hallmarks of PD are progressive loss of
dopaminergic neurons in the substantia nigra pars compacta (SNc)
and microscopic proteinaceous inclusions, composed mainly of
aggregated fibrillar a-synuclein in neurons and glia [2,3]. a-
Synuclein, an abundant presynaptic protein in the central nervous
system (CNS), consists of a 140 amino-acid sequence that is highly
homologous across human, rat and mouse [3]. Although the
precise mechanisms of PD pathogenesis are only partially un-
derstood, it is now widely accepted that the accumulation and
aggregation of a-synuclein plays a crucial role in the pathogenesis
of PD. a-Synuclein has been tightly linked to PD [4,5] and other
related neurodegenerative disorders such as multiple systems
atrophy (MSA), Hallervorden-Spatz disease, neurodegeneration
with brain iron accumulation type-1, and Niemann-Pick Type C
Disease [6,7]. Additionally, over expression of a-synuclein in
transgenic models has been shown to induce the formation of PD-
like pathological phenotypes and behavior, despite absence of
neuronal loss in the CNS [8,9]. a-Synuclein is considered
a cytosolic protein, and consequently its pathogenic effect was
assumed limited to the cytoplasm of single cells [10]. However,
recent studies have suggested that a-synuclein also has extracel-
lular pathogenic effects [11,12,13,14]. a-Synuclein has been
detected in blood plasma and cerebrospinal fluid in both
monomeric and oligomeric forms [11,12,13,14], and the presence
of significantly elevated levels of oligomeric species of a-synuclein
has been reported in plasma and cerebrospinal fluid samples from
patients with PD [12]. Furthermore, various studies have shown
that the extracellular addition of aggregated a-synuclein to culture
medium is cytotoxic [15,16,17,18,19,20,21].
It has been reported that cigarette smoking is associated with
a lower incidence of PD, attributed to a neuroprotective effect of
nicotine through the activation of nicotinic acetylcholine receptors
(nAChRs) [22,23,24,25]. Previous studies indicate extensive
expression and function of the nAChRs in midbrain dopaminergic
neurons [26,27,28,29], and a decrease of nAChRs, especially
a4b2-nAChR and a6b2-nAChR binding sites has been observed
in PD patients’ brain [30,31,32,33]. Moreover, recent evidence
suggests possible roles for nAChRs as potential targets for a-
synuclein-induced neurotoxicity resulting in cholinergic hypofunc-
tion and neuronal degeneration in basal ganglia [26,27,33].
Collectively, these findings point to a possible abnormality of
nAChRs assembly and function in PD and highlight nAChRs as
potential targets to prevent or treat PD. However, the link between
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nAChRs and a-synuclein, the major pathogen in PD, remains
obscure and undefined, and there is little evidence indicating
whether a-synuclein, particularly different forms of a-synuclein,
can directly affect nAChRs function.
Considering the significant loss of nAChRs in PD brain with a-
synuclein over expression, the neurotoxicity of a-synuclein to SNc
dopaminergic neurons, the extensive distribution of cholinergic
innervations and their receptors in SNc dopaminergic neurons,
and the neuroprotective effects provided by nAChR activation
[27,28,29], it is reasonable to hypothesize that a-synuclein might
perturb cholinergic signaling by impairing nAChRs function. To
test this hypothesis, in the present study we employed patch-clamp
techniques combined with size exclusion chromatography and
atomic force microcopy (AFM) analyses to examine and elucidate
the acute effects of specific forms of a-synuclein on the function of
human a4b2-nAChRs heterologously expressed in the human SH-
EP1 cell line.
Methods
Heterologously Expressed Human a4b2-, a7- and a4b4
nAChRs in SH-EP1 Cells
Human a4, a7, b2, and b4 subunits were subcloned into
pcDNA3.1-zeocin and pcDNA3.1-hygromycin vectors, and trans-
fected using established techniques [34,35,36] into native nAChR-
null SH-EP1 cells [37] to create the SH-EP1-ha4b2 cell line. For
this and all other methods, manipulations were conducted at room
temperature (2361uC) unless otherwise noted. Briefly, 3 million
SH-EP1 cells in 0.5 ml of 20 mm HEPES, 87 mm NaCl, 5 mm
KCl, 0.7 mm NaHPO4, 6 mm dextrose, pH 7.05, in an electro-
poration cuvette were mixed with a7, a4+b2, or a4+b4 subunit
cDNA constructs. Samples were subjected to electroporation (Bio-
Rad Gene Pulsar model 1652076) at 960 microfarads and 200
volts. After electroporation, cells were suspended to 5 ml in
complete medium [38], and 1-ml aliquots were added to 12-ml
aliquots of medium in each of five 100-mm dishes before returning
Figure 1. Characterization of a-synuclein oligomeric species by size exclusion chromatography. A. AFM image of a-synuclein pre-
incubated at 37˚C for 7 days. B. Fibrillar aggregates of a-synuclein. C and D. The size of particles was measured on the AFM height images by using
Scanning Probe Image Processor 4.5.5 (Image Metrology A/S, Hoesholm, Denmark). The typical height of a-synuclein oligomers (C) is at 2–3 nm,
comparatively the height of fibrils (D) is at 7–8 nm.
doi:10.1371/journal.pone.0055886.g001
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the cells to an incubator at 37uC. 48 h later, positive selection of
incubated cells was initiated by supplementing the medium with
0.25 mg/ml zeocin (Invitrogen, NY) and 0.4 mg/ml hygromycin
(Calbiochem, CA). Colonies of surviving cells were selected by ring
cloning and expanded before being screened for radioligand
binding and functional evidence for nAChR expression, which led
to selection of the clone designated as the SH-EP1-human nAChR
cell line. Cells were maintained at low passage numbers in medium
with 0.25 mg/ml zeocin and 0.4 mg/ml hygromycin to ensure
stable expression of phenotype and passaged once weekly by
splitting just-confluent cultures 1/10 to maintain cells in pro-
liferative growth.
Patch-clamp Whole Cell Recordings
Conventional whole cell current recording, coupled with
techniques for fast application and removal of drugs (two-barrel
tubes, Warner Instrument), was applied in this study as previously
described [39,40,41]. Briefly, cells plated on polylysine-coated 35-
mm culture dishes were placed on the stage of an inverted
microscope (Olympus iX7, Lake Success, NY) and continuously
superfused with standard external solution (2 ml/min). Glass
microelectrodes (3–5 MV resistance between pipette and extra-
cellular solutions) were used to form tight seals (.2 GV) on the cell
surface until suction was applied to convert to conventional whole
cell recording. Cells were then voltage-clamped at a holding
potential of 260 mV, and ion currents in response to application
of ligands were measured (Axon Instruments 200 B amplifier,
Molecular Devices, Sunnyvale, CA), typically using data filtered at
2 kHz, acquired at 10 kHz, displayed and digitized on-line (Axon
Instruments Digidata 1322 series A/D board), and stored on hard
media for subsequent off-line analysis. Both pipette and whole cell
current capacitance were minimized, and the series resistance was
routinely compensated to 80%. Before series resistance compen-
sation, whole cell access resistance less than 20 MV was accepted.
Data acquisition and analyses were done using Pclamp9.2 (Axon
Instruments, Molecular Devices, Sunnyvale, CA), and results were
plotted using Origin 5.0 (Microcal, North Hampton, MA). The
drugs used in this study are nicotine bitartrate, acetylcholine,
choline and GDP-b-S, which were purchased from Sigma Aldrich
(St. Louis, MO). Amyloid peptide 1–42 was purchased from r-
Peptide (Bogart, GA), and a-synuclein was provided by Dr. Sierks.
Production and Purification of a-synuclein
a-Synuclein was prepared and purified as previously described
[19,42]. Briefly, a-synuclein plasmid was transformed into BL-21
competent cells, plated onto LB-agar plates (supplemented with
Figure 2. a-Synuclein acutely modulates ha4b2-nAChR-mediated currents. A. Effects of monomeric, oligomeric and fibrillar forms of a-
synuclein on ha4b2-nAChR- mediated whole-cell currents induced by nicotine. B. Bar graph summarizes results (peak and steady-state currents) from
replicate studies. The horizontal dashed line indicates the control value (normalized as 1.0) for the specified parameters for the nicotinic response
(induced by 3 mM nicotine) before a-synuclein treatment. Double asterisk means p,0.01. C. Comparison of effects of 10 nm a-synuclein (oligomer)
on nicotine-(with or without pretreatment of 10 nm a-synuclein) and ACh-induced currents. Whole-cell current response traces induced by nicotine
recorded from the same cell without (Black) or with a-synuclein (Red), and currents induced by ACh from another cell without (Black) or with a-
synuclein (Red), respectively. D. Bar graph summarizes results (peak and steady-state currents) from replicate studies. In all recordings, the cells were
held at a holding potential (VH) of 260 mV.
doi:10.1371/journal.pone.0055886.g002
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100 mg/ml ampicillin), and grown overnight at 37uC. Single
colonies of BL21 (DE3) were grown and purified essentially as
described [42]. a-Synuclein was lyophilized and stored at –80uC.
Production and Determination of Oligomeric and Fibrillar
a-synuclein
The lyophilized a-synuclein stock was dissolved in buffer
(25 mM Tris-HCl and 150 mM NaCl, pH 7.4) to a concentration
of 70 mM. Oligomeric aggregates of a-synuclein were obtained by
incubating at 37 uC for 7–10 days without shaking. Fibrils were
obtained upon longer incubation up to 35 days. Atomic force
microscopy (AFM) was used to determine the morphologies of the
synthetically prepared a-synuclein aggregates. Topographic AFM
images were obtained in air at room temperature using a Tapping
Mode AFM with a Nanoscope IIIa controller (Veeco, Santa
Barbara, CA). Images were acquired using oxide sharpened Si3N4
AFM tips (k = 40 N/m, fo ,300 kHz) (Model: OTESPA, Veeco,
Santa Barbara, CA) at scan rates of 2–3 Hz and at scan resolution
of 512 samples per line. Images were subjected to 2nd order
polynomial flattening as needed to reduce the effects of image
bowing and tilt. AFM images were analyzed with the Scanning
Probe Imaging Processor (SPIP) software (Image Metrology, www.
imagemet.com) to generate height distribution histograms for each
sample.
Data Analysis and Statistics
nAChR acute desensitization (the decline in inward current
amplitude over the course of agonist application) was analyzed for
decay half-time (t; t=0.693/k for decay rate constant k), peak
current (Ip), and steady-state current (Is), by fitting to the mono- (or
double-) exponential expression I= [(Ip2Is) e
2kt]+Is (or I= [(Ip2Ii)
e2k1t]+[(Ii2Is) e2k2t]+Is, where Ii is the intermediate level of current
and k1 and k2 are rate constants from the two separate decay
processes). The statistical significance of the comparison between
two groups of matched data sets was assessed as p,0.05 using two-
tailed Student’s t-test. All values are expressed as mean 6 SEM.
For statistical analysis of data from multiple groups of data, one-
way or multivariate ANOVA followed by appropriate test were
applied. All experiments were performed at room temperature
(2361uC). Dose-response profiles were fit to the Hill equation and
analyzed using Prizm 3.0.
Results
Oligomeric a-synuclein Inhibits ha4b2-nAChR-mediated
Whole-cell Currents
Morphologically distinct oligomeric and fibrillar forms of a-
synuclein were generated by incubating monomeric a-synuclein
for different lengths of time and aggregate morphologies were
analyzed by AFM (Fig. 1A and B). Initial experiments were
designed to examine the acute effects of different forms of a-
synuclein (10 nM monomeric equivalent) on ha4b2-nAChR-
mediated currents. Oligomeric but not monomeric or fibrillar
forms of a-synuclein inhibited nicotine-induced whole-cell currents
(Fig. 2A). Within 2 min of pretreatment, oligomeric a-synuclein
inhibited the nicotine-induced peak (reduced to 77.964.1% of
control values for nicotine, n=8, p,0.01, t-test; Fig. 2A and B)
and steady-state currents (reduced to 82.862.3% of control values,
n=8, p,0.01, t-test; Fig. 2B). Similarly, oligomeric a-synuclein
inhibited the ACh-induced peak (reduced to 81.564.2% of control
Figure 3. Effects of different morphological sizes of a-synuclein oligomers on ha4b2-nAChR function. A. Typical traces illustrating the
effects of 10 nM large oligomeric a-synuclein [a-syn (L), .4 nm] on 3 mM nicotine-induced whole-cell currents recorded from ha4b2-nAChRs
expressed in SHEP1 cells. B. Representative typical traces of nicotine-induced whole-cell currents in the absence and presence of monomeric or small
oligomeric a-synuclein (2–4 nm). C. Summary of experimental results from A and B. Each symbol was averaged from 6 cells tested. The vertical bars
indicate Mean 6 SE. The single asterisk means p,0.05, the double asterisk means p,0.01.
doi:10.1371/journal.pone.0055886.g003
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values, n=8, p,0.01, t-test) and steady-state whole cell currents
(reduced to 78.361.9% of control values, n = 8, p,0.01, t-test;
Fig. 2C and D). However, without pretreatment, 10 nM
oligomeric a-synuclein (co-application with nicotine) did not
exhibit significant inhibition of peak current responses to nicotine
(Fig. 2C and D; 93.7% 68.2, n= 8, p.0.05, one-way ANOVA).
Taken together, these data suggest that oligomeric a-synuclein
aggregates acutely inhibit ha4b2-nAChR function.
a-Synuclein Differentially Inhibits ha4b2-nAChR-
mediated Whole-cell Currents Depending on Aggregate
Morphology
To further characterize the specific aggregate morphologies of
a-synuclein involved in altering ha4b2-nAChR function, we used
size-exclusion chromatography to separate a 7-day pre-aggregated
a-synuclein sample into different aggregated species. The 7-day
aggregated sample contains high concentrations of different
oligomeric a-synuclein species. We obtained three distinct
aggregated forms of a-synuclein particles from 7-day oligomeric
aggregates and determined the height distribution of these
particles by AFM as previously described [10], where the largest
aggregate have heights greater than 4 nm, smaller aggregates have
heights between 1 and 4 nm and monomeric particles have
heights less than 1 nm [10]. Therefore, we can obtain samples
predominantly containing large oligomeric (.4 nm), small oligo-
meric (1–4-nm), or monomeric a-synuclein.
We compared the effects of the morphologically distinct
oligomeric a-synuclein aggregates on ha4b2-nAChR-mediated
whole-cell currents. While the large oligomeric a-synuclein
aggregates significantly inhibited ha4b2-nAChR-mediated
whole-cell currents (Fig. 3A), the small aggregates or monomers
did not (Fig. 3B). Statistical analysis showed that after 10 min
exposure of large oligomeric, small oligomeric or monomeric a-
synuclein, the nicotinic responses (normalized peak amplitude)
were reduced to 63.563.9% (n= 6, p,0.05 or p,0.01, multi-
variate ANOVA), 93.265.6% (n= 6, p.0.05, multi-variate
ANOVA) or 92.566.3% (n= 6, p.0.05, multi-variate ANOVA),
respectively. These findings suggest that the inhibition of ha4b2-
nAChR-mediated whole-cell currents by oligomeric a-synuclein is
mediated by large size oligomeric a-synuclein.
a-Synuclein Inhibits Human a4b2-nAChR-mediated
Currents in Non-competitive
To characterize the inhibitory effects on ha4b2-nAChR
function induced by large oligomeric a-synuclein, we performed
a series of studies using different concentrations of aggregated a-
synuclein. Nicotine (3 mM, ,EC50 concentration) was used as an
agonist to activate ha4b2-nAChR expressed in SH-EP1 cells. a-
Synuclein inhibited nicotine-induced whole-cell currents in
a concentration-dependent manner (Fig. 4A and B; n = 6). Dose-
dependent profiles of nicotine-induced whole-cell peak currents in
the presence or absence of 10 nM aggregated a-synuclein
Figure 4. a-Synuclein inhibits ha4b2-nAChR-mediated currents in a dose-dependent and non-competitive manner. A. Representative
typical traces (recorded from the same cell) of nicotine-induced whole-cell currents in the presence of different concentrations of large oligomeric a-
synuclein. B. Summary of pool results for the effects of different concentrations of a-synuclein. C. Effects of a-synuclein (10 nM, large oligomeric) on
the concentration-response curves of ha4b2-nAChR-mediated whole-cell currents. Functional fit to the logistic equation indicates that in the
presence of a-synuclein, the maximal current response in the agonist dose-response profile was significantly reduced without change of apparent
EC50 for agonist (nicotine), suggesting a non-competitive inhibition. All symbols were normalized to the peak current induced by 100 mM nicotine,
(averaged from 6 cells for nicotine, and 6 cells for nicotine plus 10 nM a-synuclein). In all recordings (A, B and C), the cells were held at a holding
potential (VH) of 260 mV. In B, the double asterisk means p,0.01. Vertical bars indicate SEM.
doi:10.1371/journal.pone.0055886.g004
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(monomeric equivalent) showed a significant reduction in the
maximal concentration of the nicotine-induced peak current but
no change in nicotine EC50 values and Hill coefficients (2.760.6
and 1.060.08, for nicotine alone, n=8; 3.660.8 and 1.160.07 for
nicotine plus 10 nM a-synuclein, n=8, p.0.05; t-test, Fig. 4C).
These results suggest a non-competitive mechanism of a-
synuclein–mediated inhibition.
Effects of Large Oligomeric a-synuclein on Different
nAChR Subtypes
Since large oligomeric a-synuclein inhibited ha4b2-nAChR
currents, we studied if there was a differential effect of this a-
synuclein aggregate species on different nAChR subtypes. We
compared effects of the large oligomeric a-synuclein on ha4b2-,
ha7- and ha4b4-nAChRs heterologously expressed in an SH-EP1
cell line. The ha4b2- and ha4b4-nAChRs were activated using
3 mM nicotine, while ha7-nAChR was activated using 3 mM
choline. The results indicate that large oligomeric a-synuclein (at
a pathophysiologically relevant concentration of 10 nM mono-
meric equivalent) [43] inhibited nicotinic peak current responses
mediated by ha4b2-nAChRs, but not the current responses
mediated by either ha7- or ha4b4-nAChRs (Fig. 5A). Statistical
analysis showed that large oligomeric a-synuclein species reduced
the peak amplitude of ha4b2-nAChR-mediated current to
62.963.7% (n= 6, p,0.01, multi-variate ANOVA); of ha7-
nAChR-mediated current to 93.167.9% (n= 6, p.0.05, multi-
variate ANOVA); and of ha4b4-nAChR-mediated current to
96.563.8% (n= 6, p.0.05, multi-variate ANOVA), respectively.
These results indicate that the ha4b2-nAChRs are more sensitive
to a-synuclein than ha7- and ha4b4-nAChRs.
Mechanisms Involved in a-synuclein-induced Inhibition
of ha4b2-nAChR Function
Since oligomeric a-synuclein selectively inhibits ha4b2-nAChRs
function, we next determined whether a-synuclein was functioning
through either of two different potential mechanisms: 1) via
a mechanism of open channel block, or 2) via induction of ha4b2-
nAChR internalization. To test whether a-synuclein-induced
inhibition operated through the open channel block mechanism,
we repeatedly applied 3 mM nicotine in the continuous presence of
10 nM large oligomeric a-synuclein. Repeated application of
nicotine (2 min interval) in the presence of 10 nM a-synuclein for
10 min led to a reduction of nAChR response (Fig. 6Aa), while
continuous application of a-synuclein for 10 min without re-
Figure 5. a-Synuclein inhibits ha4b2- but not a7- or a4b4-
nAChR function. A. Representative whole-cell current traces com-
paring effects of 10 nM a-synuclein on a4b2-, a7-, and a4b4-nAChRs
function. B. Summary of the effects of 10 nM a-synuclein on the peak
currents for responses mediated by human a4b2-nAChRs (triangle), a7-
nAChRs (diamond), or a4b4-nAChRs (square). The asterisk indicates
p,0.05 and the double asterisk indicates p,0.01. Vertical bars indicate
SEM.
doi:10.1371/journal.pone.0055886.g005
Figure 6. a-Synuclein is not an open-channel blocker to ha4b2-
nAChR. A. Representative ha4b2-nAChR mediated whole-cell currents
induced by repetitive applications nicotine (4 sec exposure at an
interval of 2 min). The first response was recorded as controls. In Aa,
nicotine exposures were repeated at 2-min intervals in the presence of
10 nM a-synuclein for 10 min, and subsequent response to nicotine
was recorded after 6 min of washout of a-synuclein. In Ab, nicotine was
applied at the end of the a-synuclein treatment (10 min), and
a subsequent response to nicotine was recorded after 6 min of
washout of a-synuclein. B. Bar graph summarizes replicated recordings
of effects of 10 nM a-synuclein on nicotinic responses with and without
repeated nicotine exposure. Data were collected from 8 cells in each
group tested.
doi:10.1371/journal.pone.0055886.g006
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petitive exposure to nicotine led to similar inhibition (Fig. 6Ab).
The peak component of repetitive nicotine-induced current was
reduced to 70.865.8% (Fig. 6Aa, n = 8, p,0.01, t-test) and by
non-repetitive challenges of nicotine, the peak current was reduced
to 67.566.9% (Fig. 6Ab, n = 8, p,0.01, t-test). No statistical
significance in the nicotine-induced currents was observed
between the two protocols described above (Fig.6B, n= 8,
p.0.05, t-test). Thus, 10 nM large oligomeric a-synuclein did
not show clear signs of use-dependent inhibition of ha4b2-
nAChRs (Fig. 6A and B). The absence of a use-dependence
feature suggests that non-competitive inhibition of ha4b2-nAChR
function by a-synuclein is not mediated through an open channel
block. To investigate whether or not a-synuclein-induced ha4b2-
nAChR internalization is involved, patched cells were preloaded
with GDP-b-S (600 mM) for 20 min, which has previously been
reported to prevent a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionate receptor endocytosis [44]. GDP-b-S treatment neither
prevented a-synuclein-mediated inhibition nor improved ha4b2-
nAChR functional recovery from washout of a-synuclein (Fig. 7, A
and B). These data suggest that inhibition of ha4b2-nAChR
function by a-synuclein is also not mediated by ha4b2-nAChR
internalization through a process affecting a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate receptors.
Discussion
In the present study, we show that pathologically-relevant levels
(10 nM monomeric equivalent) [43] of aggregated a-synuclein
inhibit human a4b2-nAChR function. We find that larger
oligomeric a-synuclein aggregate species (.4 nm) but not
monomeric, fibrillar or smaller a-synuclein aggregates (2–4 nm)
are responsible for this partial inhibitory effect on a4b2-nAChRs.
The partial inhibitory effect of a-synuclein on ha4b2-nAChRs
exhibits a mechanism that is dose-dependent, non-competitive,
non use-dependent and non-internalization based. Interestingly,
the a-synuclein-induced inhibition occurs more profoundly in
a4b2-nAChRs than in other nAChR subtypes such as a7- or
a4b4-nAChRs, indicating subtype selectivity.
Distinguish Inhibitory Effects on nAChRs by Different
Forms of a-synuclein
Misfolding and aggregation of a-synuclein has been implicated
in the pathogenesis of numerous neurodegenerative diseases,
particularly in PD [4,45]. Different oligomeric a-synuclein species
can be generated as intermediate species during the transition
from monomeric to fibrillar aggregates [46,47]. Accumulating
evidence indicates that oligomeric a-synuclein is the most toxic
species responsible for neurodegeneration and neuronal loss in PD
[48,49,50]. nAChRs have been linked to pathogenesis of PD and
recent evidence suggests possible roles for nAChRs as potential
Figure 7. Inhibition of ha4b2-nAChRs by a-synuclein is not mediated through receptor turnover or internalization. A. Representative
whole-cell current traces using typical tris-filled pipettes (Aa) and the tris-filled pipettes supplemented with 600 mM GDP-b-S (Ab). Initial responses to
nicotine were measured after 20 min of the formation of conventional whole-cell recording (infusion of intracellular GDP-b-S into recorded cell).
Sequence of drug applications are indicated as horizontal bars. B. Temporal patterns show the similar effects of 10 nM a-synuclein on nicotinic
responses with (n = 8) and without (n = 8) GDP-b-S in the pipette solution. The double asterisks indicate p,0.01 compared before and after a-
synuclein exposure, while # means p.0.05 compared between the pipette solution with (red) and without (black) GDP-b-S.
doi:10.1371/journal.pone.0055886.g007
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targets for a-synuclein-induced neurotoxicity manifest as cholin-
ergic hypofunction in PD [26,27,33]. However, whether or not a-
synuclein directly modulates nAChR function, especially whether
specific aggregated morphologies of a-synuclein interact with
different subtypes of nAChRs has not been examined previously.
Several studies have shown that different aggregated a-synuclein
forms added extracellularly to the culture medium can have
different cytotoxic effects [15,16,17,18,20,21]. Here we show that
oligomeric but not monomeric or fibrillar a-synuclein directly
inhibits the function of ha4b2-nAChRs. To further study the
effects of oligomeric a-synuclein on ha4b2-nAChRs, we de-
termined whether there are any differences in the inhibitory effects
of different aggregate forms of a-synuclein toward ha4b2-
nAChRs. Size exclusion chromatography was used to separate
several distinct aggregate species of a-synuclein. We show that
a large oligomeric a-synuclein aggregate species (predominantly,
.4 nm, 99.6%), but not small aggregate species (2–4 nm, 87.4%)
significantly inhibited ha4b2-nAChRs function, indicating that
morphologically distinct forms of a-synuclein result in different
nAChRs inhibition potency. These studies support the hypothesis
that aggregated a-synuclein, particularly oligomeric species, may
target ha4b2-nAChRs expressing dopaminergic neurons during
the pathogenesis of PD and may account for the loss of cholinergic
input to dopaminergic neurons [30,51].
Possible Mechanisms of a-synuclein-mediated Inhibition
of ha4b2-nAChR Function
These results clearly demonstrate that oligomeric a-synuclein
selectively and partially inhibits ha4b2-nAChR function. The
finding of non-competitive antagonism of ha4b2-nAChRs by
oligomeric a-synuclein suggests that the large oligomeric a-
synuclein species acts as a non-competitive antagonist of ha4b2-
nAChRs under our experimental conditions. Our results also
demonstrate that oligomeric a-synuclein, at concentrations from
1 nM to 1 mM, failed to directly induce whole-cell current
responses from cells expressing ha4b2- or ha7-nAChRs or from
untransfected cells (data not shown). These results indicate that a-
synuclein in our hands does not have properties of a nAChR
agonist.
Additionally, our data show no use-dependence of large
oligomeric a-synuclein-induced inhibition on ha4b2-nAChR
function, suggesting that the inhibitory effects are not mediated
by open channel block, although the persistence in functional
block after washout of fluid phase a-synuclein suggests a ‘‘linger-
ing’’ effect of the aggregates. We found that pretreatment with
large oligomeric a-synuclein is necessary to induce convincing
inhibition of ha4b2-nAChR-mediated whole-cell currents. How-
ever, the nature of this inhibition is still unknown. One potential
explanation is that there is an aggregated a-synuclein-driven long-
lasting closed conformation of nAChRs. This idea is supported by
the present observation that long exposure times (10 min) to large
oligomeric a-synuclein aggregates leads to persistent loss of ha4b2-
nAChR function, and any loss of nAChR function does not appear
to be mediated via a-synuclein-induced ha4b2-nAChR internal-
ization. This conclusion is based on the observation that GDP-b-S
(600 mM) fails to prevent the loss of ha4b2-nAChR function
induced by a-synuclein pre-incubation. On the other hand, the
inhibition of ha4b2-nAChR function by a-synuclein is partial,
non-competitive, and reversible, which is similar to amyloid-
induced inhibition on ha4b2-nAChR [5]. In fact, pre-treatment
with oligomeric amyloid 1–42 (1 nM) for 10 min prevented a-
synuclein-induced inhibition in ha4b2-nAChR-mediated currents
(Figure S1), suggesting a mechanism reminiscent of a negative
allosteric inhibitor. The relatively large size of the inhibitory
species may be indicative of a physical interaction partially
inhibiting ha4b2-nAChR function but not totally blocking it.
In addition, it is also interesting that a-synuclein selectively
inhibits ha4b2-nAChR subtype rather than ha7- or ha4b4-
nAChR subtypes. Although it has been reported that a7 nAChRs,
shown to be unaffected in the present report by a-synuclein, are
upregulated in PD [31], there are experimental differences
between our studies and that of Guan et al. that make direct
comparison difficult. For example, we examined direct effects of
acute exposure of a-synuclein on nAChR function using
transfected nAChRs in cell lines, while Guan et al. reported the
nAChR subunit expression and binding using PD brain tissue
[31]. The potential effects of a-synuclein-induced inhibition
remain to be examined on other nAChR subtypes, such as
ha6b2-, ha6b2b3- and ha3b4-nAChR, which may serve as
a potential target for PD therapeutics as well. These a6-containing
nAChR subtypes may be important since they show significant
declines in PD animal models. However, due to difficulties in
stably expressing these heterologous a6-containing receptors in
SH-EP-1 cell lines, we were not able to test the effects of a-
synuclein on these subtypes of nAChRs here.
Pathological Relevance of a4b2-nAChR Dysfunction and
PD
Neuronal nicotinic receptors that bind radiolabeled nicotine
with the highest affinity contain a4 subunits (a4*-nAChR) [52,53].
Immunoassays have shown that the predominant, naturally
expressed form of the a4*-nAChR in the vertebrate brain contains
a4 and b2 subunits (a4b2-nAChR) [54,55]. Evidence indicates
that a consistent, significant loss of a4*-nAChRs has been
observed at autopsy in PD brain [31,56,57,58]. The major
pathological features of PD are a-synuclein protein deposition,
lewy body formation, and a severe dopaminergic deficit [32]. It
has been shown that the a-synuclein protein is a major constituent
of lewy bodies, a neuropathologic hallmark of PD [32]. However,
links between soluble a-synuclein accumulation and cholinergic
dysfunction remain unclear. The present study characterized the
aggregated morphologies of a-synuclein by size exclusion chro-
matography and AFM. This enabled us to distinguish different
aggregated a-synuclein species. Oligomeric a-synuclein, particu-
larly the larger oligomeric a-synuclein aggregates studied here,
selectively inhibits ha4b2-nAChR function in a dose-dependent
and non-competitive manner, providing the basis for a new
hypothesis that a-synuclein can directly modulate ha4b2-nAChR
function, which in turn may contribute to cholinergic signaling
deficits in PD.
Although a partial inhibitory effect of a-synuclein on ha4b2-
nAChR function was observed at pathophysiology relevant
concentrations, further investigation is needed to determine
whether such an effect will be large enough to be clinically
relevant. It is also noteworthy that a7-nAChR binding sites are
increased in PD brain tissues, suggesting that a7-nAChR might be
affected by a-synuclein during PD pathogenesis. However, under
our conditions, direct acute exposure of a-synuclein fails to affect
ha7-nAChR function. One possible interpretation is that there
may be other confounders during chronic a-synuclein accumula-
tion to affect a7-nAChR expression in vivo, which cannot be
mimicked by acute, in vitro experiments. Our perspective on
a primary role for ha4b2-nAChRs in low concentration effects of
a-synuclein complements other findings that the modulation of
nAChR function by a-synuclein could be pathologically relevant
[27,32,33].
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Conclusion
Collectively, our findings demonstrate for the first time that
pathologically-relevant concentrations of aggregated oligomeric a-
synuclein directly inhibit neuronal human a4b2-nAChR function.
We find that large oligomeric a-synuclein aggregates (.4 nm), but
not monomeric or fibrillar a-synuclein, selectively inhibit ha4b2-
nAChR function starting at 10 nM (monomeric equivalent).
Specifically, we show that predominantly larger oligomeric a-
synuclein aggregates (.4 nm) but not smaller species (,4 nm)
potently inhibit ha4b2-nAChRs mediated whole-cell currents.
Furthermore, we elucidate pharmacological mechanisms of a-
synuclein–induced inhibition, which includes dose-dependent,
non-competitive, non-use-dependent manners, and this inhibition
is not mediated through nAChR internalization. Finally, we
demonstrate that the functional inhibition by a-synuclein exhibits
nAChR subunit selectivity, occurring more profoundly in a4b2-
nAChRs than in other nAChR subtypes such as a7- or a4b4-
nAChRs. Our findings, along with previous reports on the roles of
a6b2*-nAChRs in PD pathogenesis [33], suggests that nAChRs
are sensitive targets for a-synuclein toxicity. The a4b2-nAChRs
are sensitive to morphologically specific and pathologically
relevant concentrations of a-synuclein, suggesting that novel
strategies for PD therapy could involve amelioration of specific
aggregated a-synuclein-induced a4b2-nAChR functional deficits
and/or perhaps preservation of a4b2-nAChR function.
Supporting Information
Figure S1 Effects of pretreatment of oligomeric amyloid (Ab1-
42) on a-synuclein-induced inhibition of human a4b2-nAChRs
heterologously expressed in SH-EP1 cell line. We found that after
10 min pre-treatment with 1 nM oligomeric Ab1-42, 3 mM
nicotine (around EC50 concentration)-induced inward current
was reduced (Figure S1A, blue trace). Thereafter, we immediately
added 10 nM a-synuclein (in the continuous presence of 1 nM
Ab1-42) for 10 min, and then tested nicotinic response. However,
we did not observe further reduction of nicotine-induced inward
current (Figure S1A, red trace). Statistic analysis showed that Ab1-
42 pre-treatment significantly reduced both peak and steady-state
components of nicotine-induced-whole-cell current (Figure S1B,
n = 6, p,0.01), while in the presence of Ab1-42, a-synuclein failed
to further reduce this current response (p.0.05 between Ab1-42
and a-synuclein treated group), indicated as no significance (NS) in
the figure. These results suggest that both oligomeric molecules of
Ab1-42 and a-synuclein likely bind to a common negative
allosteric site to reduce human a4b2-nAChR function.
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